<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Catheter ablation to prevent recurrent atrial fibrillation: Anticoagulation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Catheter ablation to prevent recurrent atrial fibrillation: Anticoagulation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Catheter ablation to prevent recurrent atrial fibrillation: Anticoagulation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rod Passman, MD, MSCE</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley P Knight, MD, FACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">N A Mark Estes, III, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1041763944"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Ischemic stroke and systemic embolization are major causes of death and disability in patients with atrial fibrillation (AF). This topic will focus on the role of anticoagulant therapy to prevent embolization in patients scheduled to undergo catheter ablation (CA). The role of anticoagulant therapy in the broad population of patients with AF is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p>Other aspects of CA are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/949.html" rel="external">"Atrial fibrillation: Catheter ablation"</a> and  <a class="medical medical_review" href="/z/d/html/93920.html" rel="external">"Maintenance of sinus rhythm in atrial fibrillation: Catheter ablation versus antiarrhythmic drug therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1007.html" rel="external">"Overview of catheter ablation of cardiac arrhythmias"</a> and  <a class="medical medical_basics" href="/z/d/html/15668.html" rel="external">"Patient education: Catheter ablation for the heart (The Basics)"</a> and  <a class="medical medical_review" href="/z/d/html/95704.html" rel="external">"Catheter ablation for the treatment of atrial fibrillation: Technical considerations for non-electrophysiologists"</a>.)</p><p class="headingAnchor" id="H20402004"><span class="h1">OUR APPROACH TO ANTICOAGULATION</span><span class="headingEndMark"> — </span>There are three periods when a decision or decisions have to be made about anticoagulation in a patient scheduled for catheter ablation (CA).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preprocedural </strong>– We effectively anticoagulate most patients, irrespective of CHA<sub>2</sub>DS<sub>2</sub>-VASC score  (<a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">table 1</a>) or presence or absence of sinus rhythm, with either a vitamin K antagonist (VKA) or a direct oral anticoagulant (DOAC; also referred to as non-vitamin K oral anticoagulants [NOAC]) for at least three weeks prior to CA. It is reasonable to not use preprocedural anticoagulation in AF patients in sinus rhythm (and who are likely to remain in sinus rhythm for three weeks prior to the procedure) with a CHA<sub>2</sub>DS<sub>2</sub>-VASC score of 0. (See <a class="local">'Preprocedural issues'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Periprocedural</strong> – We continue VKA in the periprocedural period. For most patients taking once-a-day DOACs, we either continue them uninterrupted or hold the dose the day before and the morning of the procedure. For twice-a-day DOACs, some of our experts hold both doses the day before the procedure while others hold only the evening dose before the procedure; no drug is given the morning of the procedure in these cases. Uninterrupted DOAC is commonly used and has been shown to have similar rates of thromboembolic and bleeding events as minimally interrupted DOAC use [<a href="#rid1">1</a>]. Studies support the fact that uninterrupted DOACs may be superior to uninterrupted <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> for patients who require continued anticoagulation due to high risk of thromboembolism [<a href="#rid2">2</a>]. All patients receive a continuous infusion of <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH); the activated clotting time is maintained at greater than 300 seconds during the procedure. (See <a class="local">'Periprocedural issues'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postprocedural </strong>– UFH is stopped at the end of the procedure and the sheaths are pulled when the activated clotting time is &lt;180 to 200 seconds.</p><p></p><p class="bulletIndent1">For patients previously taking a VKA, the next dose is given approximately 24 hours after the prior dose. For those patients in whom the international normalized ratio was &lt;2.0 prior to the procedure, we restart UFH without a bolus six hours after sheath pull, increase the oral <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> the night of the procedure, and we continue UFH until the INR is 2.0. Another reasonable approach is to stop UFH the morning after the procedure and start low molecular weight heparin, usually at half the normal dose (0.5 mg/kg twice daily) to avoid bleeding. Substituting DOAC for VKA can also be considered at this time. (See <a class="local">'Postprocedural anticoagulation'</a> below.)</p><p></p><p class="bulletIndent1">For patients previously taking a DOAC, we suggest restarting it six hours after sheath removal (and in the absence of any related bleeding). Some experts give intravenous heparin (no bolus; drip at 1000 to 1200 units per hour) or low molecular weight heparin (<a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> 0.5 mg/kg) starting six hours after sheath pull, that is uncomplicated by bleeding, and continue until the morning after the ablation. Most experts no longer give a heparin after sheath pull.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term </strong>– We continue oral therapy with the previously prescribed oral anticoagulant for two to three months regardless of CHA<sub>2</sub>DS<sub>2</sub>-VASc score. After this period, the decision to continue on long-term anticoagulation is based on the patients underlying stroke risk regardless of whether rhythm control has been achieved. For those patients whose risk for embolization is very low, such as those with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0  (<a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">table 1</a>), we stop anticoagulation at the two-to-three-month visit.</p><p></p><p class="headingAnchor" id="H1041763951"><span class="h1">INCIDENCE, TIMING, AND MECHANISM OF EMBOLISM</span><span class="headingEndMark"> — </span>The risk of stroke, transient ischemic attack, or other manifestation of embolization is increased at the time of catheter ablation (CA) and is in the range of 0.4 to 2.0 percent [<a href="#rid3">3-5</a>]. These rates come from studies of patients who are receiving anticoagulant therapy and would be higher off such treatment. Most strokes occur within 24 to 48 hours after the procedure [<a href="#rid5">5</a>]. However, embolic events thought attributable to the procedure have been reported to occur for up to one week [<a href="#rid6">6</a>].</p><p>The following are potential causes of periprocedural embolization:</p><p class="bulletIndent1"><span class="glyph">●</span>Withdrawal of anticoagulation before the procedure</p><p class="bulletIndent1"><span class="glyph">●</span>Catheter manipulation within the left atrium, which may dislodge preexisting thrombus</p><p class="bulletIndent1"><span class="glyph">●</span>Catheter trauma to the left atrial endothelium, which increases the risk of thrombus formation</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombus formation on the ablation catheters or left atrial guide sheaths</p><p class="bulletIndent1"><span class="glyph">●</span>Conversion to sinus rhythm during the procedure in some patients (see  <a class="medical medical_review" href="/z/d/html/906.html" rel="external">"Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"</a>)</p><p></p><p class="headingAnchor" id="H1041764011"><span class="h2">Asymptomatic embolism</span><span class="headingEndMark"> — </span>Not all emboli to the brain are symptomatic. Multiple magnetic resonance imaging (MRI) studies performed within 24 hours after CA have demonstrated new cerebral lesions in 7 to 44 percent of asymptomatic patients [<a href="#rid7">7-12</a>]. These lesions are presumed secondary to microemboli [<a href="#rid13">13</a>].</p><p>Studies of the subsequent impact of these lesions on neurocognitive function have come to somewhat differing conclusions as to the significance of these lesions:</p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of cognitive impairment after radiofrequency CA (RFA) was evaluated in a study of 150 patients: 60 undergoing ablation for paroxysmal atrial fibrillation (AF), 30 for persistent AF, 30 for supraventricular tachycardia, and 30 matched AF patients awaiting RFA (the control group) [<a href="#rid14">14</a>]. All CA patients received periprocedural <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> and most patients with AF had a CHADS<sub>2</sub> score of 0 or 1  (<a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">table 1</a>). All patients underwent eight neuropsychological tests at baseline and at 2 and 90 days after RFA. The prevalence of neurocognitive dysfunction at day 90 was 13, 20, 3, and 0 percent, respectively, in these four groups of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 37 patients with paroxysmal AF who underwent 41 CA procedures, MRI performed within 48 hours showed new brain lesions in 41 percent of patients and 44 percent of procedures [<a href="#rid10">10</a>]. Follow-up MRI at six months found glial scar in about 12 percent of those with lesions. However, there was no decline of neurocognitive function on testing performed after six months.</p><p></p><p class="headingAnchor" id="H276377316"><span class="h1">PREPROCEDURAL ISSUES</span><span class="headingEndMark"> — </span>All patients not at low risk of stroke should be treated with long-term anticoagulant therapy using one of the novel oral anticoagulants or <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>. Thus, many patients will be receiving anticoagulation when scheduled for catheter ablation (CA) and should continue their anticoagulant. (See  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants", section on 'Summary and recommendations'</a>.)</p><p>For patients <strong>not</strong> taking long-term anticoagulant therapy due to a low risk of stroke, there are no studies that have compared differing anticoagulant strategies prior to CA; thus, the optimal preprocedural anticoagulation strategy is not known. For these patients, including those in sinus rhythm, most of our experts carry out a minimum of three weeks of effective oral anticoagulation prior to the procedure. The rationale for doing so is that many episodes of atrial fibrillation (AF) are asymptomatic and these episodes will have placed the patient at risk of embolization at the time of catheter manipulation. </p><p>We also believe it is reasonable to not use preprocedural anticoagulation in AF patients in sinus rhythm (and who are likely to remain in sinus rhythm for three weeks prior to the procedure) with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0.</p><p>When three weeks of effective anticoagulant therapy has not been carried out, preprocedural transesophageal echocardiography (TEE) should be performed (see <a class="local">'Role of transesophageal echocardiography'</a> below); patients with evidence of left atrial thrombus are not candidates for CA unless it resolves with anticoagulation.</p><p class="headingAnchor" id="H377978602"><span class="h2">Choice of anticoagulant</span><span class="headingEndMark"> — </span>For patients started on oral anticoagulant therapy prior to catheter ablation, direct oral anticoagulants (DOAC; also referred to as non-vitamin K oral anticoagulants [NOAC]) are preferred over <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>. This preference is based on our preference for these agents in the general AF population [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a>.)</p><p>Most but not all observational studies comparing one NOAC to <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> have found similar efficacy [<a href="#rid16">16</a>] and safety [<a href="#rid17">17-24</a>]. At least three meta-analyses of observational studies comparing warfarin to <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> have come to similar conclusions [<a href="#rid25">25-27</a>]. A 2016 meta-analysis of 25 studies (11,686 patients) comparing DOACs with uninterrupted VKAs found no significant difference in the rate of stroke or transient ischemic attacks (odds ratio 1.35, 95% CI 0.62-2.94) and major bleeding (odds ratio 0.80, 95% CI 0.65-1.00) [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H1463619036"><span class="h2">Switching oral anticoagulant</span><span class="headingEndMark"> — </span>As stated directly above, we prefer one of the DOAC group to <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> for patients undergoing catheter ablation. For patients receiving long-term warfarin therapy, there is no evidence that switching to DOAC prior to catheter ablation improves outcomes. Thus, we do not routinely switch from warfarin to an DOAC.</p><p>We do not have a preference for one DOAC over another and thus we do not switch DOAC.</p><p class="headingAnchor" id="H27274689"><span class="h2">Role of transesophageal echocardiography</span><span class="headingEndMark"> — </span>Most experts will image the left atrial appendage prior to ablation to ensure the absence of thrombus even in those with effective preprocedural oral anticoagulation, as the presence of left atrial thrombus is a contraindication to the procedure [<a href="#rid29">29,30</a>]. TEE is often performed prior to (generally the day before) CA. Two reasons to perform TEE prior to (generally the day before) CA are that it adds significant length to the CA, and some complications of TEE, such as a retropharyngeal hematoma, can be aggravated by the <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> used during the procedure. (See  <a class="medical medical_review" href="/z/d/html/5303.html" rel="external">"Echocardiography in detection of cardiac and aortic sources of systemic embolism", section on 'LA/LAA thrombi'</a>.)</p><p>We acknowledge that some experts will omit a TEE in the lowest-risk patients who have been taking effective anticoagulant therapy for at least three weeks, such as those in sinus rhythm who have no significant structural heart disease or those with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0  (<a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">table 1</a>) [<a href="#rid30">30</a>]. These experts often prefer that a pre-ablation magnetic resonance image confirms the absence of left atrial appendage thrombus in these patients who do not undergo preprocedural TEE. In a study of 97 patients undergoing pulmonary vein isolation, contrast-enhanced MRI demonstrated 100 percent concordance with TEE for the presence and absence of left atrial appendage thrombus [<a href="#rid31">31,32</a>].</p><p>An attempt to determine the need for preprocedural TEE in patients at low risk for embolization was made in an analysis of 1058 patients who had TEE performed within 24 hours of pulmonary vein isolation [<a href="#rid33">33</a>]. The frequency of left atrial thrombus or sludge was evaluated according to the CHADS<sub>2</sub> score. (See  <a class="medical medical_review" href="/z/d/html/5303.html" rel="external">"Echocardiography in detection of cardiac and aortic sources of systemic embolism"</a>.) A CHADS<sub>2</sub> score of 0 was present in 47 percent of patients. Left atrial or left atrial appendage thrombus or sludge was found in 0.6 and 1.5 percent of all patients and the frequency increased with ascending CHADS<sub>2</sub> scores (percents in parentheses): 0 (0), 1 (2), 2 (5), 3 (9), 4 to 6 (11).</p><p>We do not use intracardiac echocardiography or computed tomography as a substitute for TEE. Each of these has been shown to be inferior in this setting [<a href="#rid34">34,35</a>].</p><p class="headingAnchor" id="H1041770091"><span class="h1">PERIPROCEDURAL ISSUES</span><span class="headingEndMark"> — </span>The two principal periprocedural anticoagulant issues are how to manage the oral anticoagulant and whether/how to use parenteral anticoagulant.</p><p class="headingAnchor" id="H2531286912"><span class="h2">Management of oral anticoagulants</span><span class="headingEndMark"> — </span>For patients taking long-term oral anticoagulant who present for catheter ablation, the approach depends on which anticoagulant the patient has been taking.</p><p class="headingAnchor" id="H2909564350"><span class="h3">Patients taking long-term vitamin K antagonist</span><span class="headingEndMark"> — </span>For patients taking a VKA prior to catheter ablation, we prefer the strategy of uninterrupted VKA to a strategy of a heparin bridge. We do not hold doses of VKA unless the international normalized ratio (INR) is &gt;3.0. (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Bridging anticoagulation'</a>.)</p><p>One randomized trial [<a href="#rid36">36</a>] and most observational studies [<a href="#rid5">5,37,38</a>] have shown that continuous anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, compared with warfarin discontinuation with a heparin bridge, is associated with a lower rate of embolization and an equivalent or lower bleeding rate [<a href="#rid39">39</a>]. In the COMPARE trial, 1584 patients with paroxysmal or persistent atrial fibrillation (AF) (see  <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation", section on 'Classification and terminology'</a>) and CHADS<sub>2 </sub>score ≥1 were randomly assigned to warfarin discontinuation two to three days before ablation and bridging with low molecular weight heparin (1 mg/kg <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> twice daily until the evening before the procedure) or continuation of therapeutic warfarin (three to four weeks with an INR 2.0 to 3.0) [<a href="#rid36">36</a>]. The primary end point of the incidence of thromboembolic events (stroke, transient ischemic attack, or systemic thromboembolism) in the 48 hours after ablation occurred more frequently with warfarin discontinuation (4.9 versus 0.25 percent; odds ratio 13, 95% CI 3.1-55.6). The incidence of major bleeding complications was similar in the two groups (0.76 versus 0.38 percent, respectively). The majority of events occurred in patients with persistent AF. One limitation of the trial is that operators were not blinded to the anticoagulation strategy.</p><p>For patients in whom a strategy of continuous anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> has been chosen, the optimal immediate-preprocedural range for the INR is not known. In a retrospective study of 1113 patients undergoing radiofrequency catheter ablation for AF, bleeding and vascular complications were less prevalent when the INR was ≥2.0 and ≤3.0 (5 percent), compared with ≤2.0 (10 percent) or ≥3.0 (12 percent) [<a href="#rid40">40</a>]. The optimal INR range was calculated to be 2.1 to 2.5.</p><p class="headingAnchor" id="H1074706469"><span class="h3">Patients taking DOACs</span><span class="headingEndMark"> — </span>In most studies that have evaluated periprocedural outcomes in patients taking direct oral anticoagulants (DOAC; also referred to as non-vitamin K oral anticoagulants [NOAC]), the DOAC was held prior to the procedure. In one trial, 326 patients undergoing AF ablation were randomized to uninterrupted DOAC, procedure day single-dose skipped DOAC, or 24-hour skipped DOAC [<a href="#rid41">41</a>]. The intraprocedural heparin dose was higher in the 24-hour skipped group, but the incidence of major bleeding and postprocedural hemoglobin levels were not significantly different among the treatment groups and different DOACs. There were no fatal events or thromboembolic complications.</p><p>For patients taking once-a-day DOACs in the morning, some operators will hold the dose the day before and also the day of the procedure. For those that take once-a-day DOACs with the evening meal or later, they may hold only a single dose the day before the procedure. For twice-a-day DOACs, some of our experts hold both doses the day before the procedure while others hold only the evening dose before the procedure and the morning of the procedure.</p><p>For many patients, especially those at particularly high risk of a periprocedural stroke, including those with a high CHA<sub>2</sub>DS<sub>2</sub>-VASc score in whom intraprocedural cardioversion is planned, no interruption of (continuous) oral anticoagulation with a DOAC is the preferred alternative to interruption. (See <a class="local">'Choice of anticoagulant'</a> above.)</p><p>Small randomized trials of <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a>, and <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> suggest that outcomes with uninterrupted DOACs are similar to those with uninterrupted <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid42">42-45</a>].</p><p class="headingAnchor" id="H3016327579"><span class="h2">Use of intravenous heparin</span><span class="headingEndMark"> — </span>As catheter ablation (CA) is associated with an increase (from baseline) in the risk of a periprocedural thromboembolic event, we recommend that all patients receive intraprocedural heparin. (See <a class="local">'Incidence, timing, and mechanism of embolism'</a> above.)</p><p>We start with a loading dose of 100 units/kg at the beginning of the procedure. Others start the loading dose before transeptal puncture, while others give half the dose before and half the dose after transeptal puncture [<a href="#rid46">46</a>]. A continuous infusion is used to maintain the activated clotting time greater than 300 seconds; the first activated clotting time is performed 10 to 15 minutes after the loading dose. Heparin is stopped at the end of the procedure and the sheaths are pulled when the activated clotting time is &lt;180 to 200 seconds. Protamine can be given after the procedure before removing vascular sheaths.</p><p>Intracardiac echocardiography is done at the end of the CA procedure to ensure that there is no pericardial effusion. If a pericardial effusion is found we take the following approach:</p><p class="bulletIndent1"><span class="glyph">●</span>For small effusions, we observe and continue with the anticoagulation protocol.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If moderate, we reverse anticoagulation and observe.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If large, we reverse anticoagulation and perform pericardiocentesis. (See  <a class="medical medical_review" href="/z/d/html/143123.html" rel="external">"Pericardial effusion: Approach to management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with hemodynamic compromise, regardless of the size of the effusion, we perform pericardiocentesis and reverse anticoagulation.</p><p></p><p class="headingAnchor" id="H1041764004"><span class="h1">POSTPROCEDURAL ANTICOAGULATION</span><span class="headingEndMark"> — </span>The approach to anticoagulation within the first 24 hours after a successful procedure is determined in large part by preprocedural anticoagulant approach (see <a class="local">'Preprocedural issues'</a> above). There have been no studies comparing one approach to another. In the absence of any related bleeding, we suggest the following approach:</p><p class="bulletIndent1"><span class="glyph">●</span>For those previously taking <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, and for whom the management of the international normalized ratio was not problematic, we suggest continuing warfarin. The first postprocedural dose should be the day after the procedure, assuming a dose was given the morning of the procedure. (See <a class="local">'Patients taking long-term vitamin K antagonist'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients taking <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> whose procedure was done with a subtherapeutic international normalized ratio, we restart intravenous heparin without a bolus six hours after sheath pull and start low molecular weight heparin the morning after the procedure. Low molecular weight heparin is continued until the international normalized ratio is therapeutic. When low molecular weight heparin is used, some of our experts give the first dose at 50 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients previously taking a direct oral anticoagulant (DOAC; also referred to as non-vitamin K oral anticoagulants [NOAC]), DOAC may be restarted four to six hours after sheath pull.</p><p></p><p class="bulletIndent1">Alternatively, some experts delay restarting these newer agents until the morning after the procedure. If the DOAC is restarted the morning after the procedure, we give either intravenous <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (no bolus; drip at 1000 to 1200 units per hour starting six hours after sheath pull and continued until the morning after the procedure) or low molecular weight heparin (<a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> 0.5 mg/kg; typically a single dose administered six hours after sheath pull).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients previously not taking any oral agent, we suggest starting either a DOAC or <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>. A first dose of either agent can be given six hours after an uncomplicated procedure. Patients started on warfarin will need to receive bridging treatment for a few days with low molecular weight heparin, as described directly above.</p><p></p><p class="headingAnchor" id="H1191924377"><span class="h1">LONG-TERM ANTICOAGULATION</span><span class="headingEndMark"> — </span>We continue oral therapy with the previously prescribed oral anticoagulant [<a href="#rid47">47</a>] for at least two months to ensure that the increased risk of embolization associated with the procedure, which lasts for about four weeks, has returned to a baseline risk and that there has been adequate time to document an absence of recurrence of atrial fibrillation (AF) for those patients in whom practitioners and patients are contemplating discontinuing anticoagulation [<a href="#rid48">48</a>]. (See <a class="local">'Incidence, timing, and mechanism of embolism'</a> above.)</p><p>After this two-month period of mandatory oral anticoagulation, we generally restore the anticoagulant regimen in place prior to the procedure. For those patients without evidence of recurrent AF and whose risk for embolization is very low, such as those with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0  (<a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">table 1</a>), we stop anticoagulation. (See  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation", section on 'CHA2DS2-VASc score'</a>.)</p><p>Some experts are comfortable stopping anticoagulation in patients with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 1  (<a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">table 1</a>) after sufficient documentation of the absence of recurrent episodes of AF. We believe this approach has not been adequately tested. Therefore, we tell patients and referring physicians that the desire to stop long-term anticoagulation is not an indication for catheter ablation (CA) by itself.</p><p>For all patients with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of &gt;1  (<a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">table 1</a>) after CA, irrespective of whether or not recurrence has been documented, we maintain the patient on long-term oral anticoagulation [<a href="#rid49">49,50</a>].</p><p>The optimal approach to chronic anticoagulation after successful CA, defined as no evidence of recurrence, is uncertain [<a href="#rid51">51</a>]. It is known that late recurrent AF occurs in 20 to 30 percent of patients, but the methods used in some studies likely underestimate the incidence [<a href="#rid52">52-55</a>]. (See  <a class="medical medical_review" href="/z/d/html/949.html" rel="external">"Atrial fibrillation: Catheter ablation", section on 'Efficacy'</a>.)</p><p>In a 2019 meta-analysis of five studies with nearly 4000 patients that evaluated safety and efficacy of long-term oral anticoagulation (OAC) compared with no OAC, the following was found during a mean follow-up of nearly 40 months [<a href="#rid56">56</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥2, OAC continuation was associated with a decrease in the risk of thromboembolic events (risk ratio [RR] 0.41, 95% CI 0.21-0.82) but an increased risk of intracranial hemorrhage (ICH; RR 5.78, 95% CI 1.33-25.08). The absolute risk decrease in thromboembolic risk was 1.14 percent, while the increase in ICH was 0.7 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0 or 1, the risk of ICH from OAC exceeded any potential decrease in thromboembolic risk.</p><p></p><p>The issue of the role of long-term anticoagulation was indirectly addressed by at least three studies that found a lower incidence of stroke comparing successful CA to antiarrhythmic drug therapy [<a href="#rid57">57-59</a>]. In a retrospective study of 174 matched pairs of AF individuals with a CHA2DS2-VASc score ≥1 who were treated with either antiarrhythmic drug therapy or CA and treated for at least three months with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, the rate of stroke/transient ischemic attack was lower with the CA group (0.59 versus 2.21 percent per year) [<a href="#rid57">57</a>]. In those individuals treated with CA and in whom there was no AF recurrence, the stroke rate was very low compared to those with recurrence (0.8 versus 5.4 percent) after a mean follow-up period of 47 months.</p><p>In addition, it is not known if asymptomatic recurrences result in a persistent thromboembolic risk in patients who have undergone CA. A low risk of stroke was reported in a series of 755 patients with longstanding persistent AF who underwent CA or a tailored approach [<a href="#rid60">60</a>]. In this cohort, anticoagulation was discontinued three months after the procedure in the majority of the 522 patients who did not have evidence of recurrent AF. During a median follow-up of 25 months, none of the patients who stopped anticoagulation had a stroke. Although these results are encouraging, the study cohort had a low baseline thromboembolic risk, with most having a CHADS2-VASc score of 0 to 2  (<a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">table 1</a>). Some of these patients, such as those with lone AF, would not require chronic oral anticoagulation whether or not they had a successful CA procedure.</p><p>The following recommendations were made in the 2019 update of the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society AF guideline [<a href="#rid61">61,62</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic anticoagulation was recommended for at least two months in all patients following CA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After two months, the decision to continue anticoagulation should be based on the patient’s risk factors for stroke and risk of bleeding, and not on the type of AF. The guideline acknowledges that recurrent episodes of AF, which may be asymptomatic, occur.</p><p></p><p>The 2019 focused update from the American Heart Association/American College of Cardiology/Heart Rhythm Society AF guideline recommends a long-term oral anticoagulation CHA<sub>2</sub>DS<sub>2</sub>-VASc score of ≥2 for men and ≥3 for women [<a href="#rid15">15</a>]. The position document on antithrombotic management in patients undergoing electrophysiological procedures states "…the decision for oral anticoagulation depends on the patient’s stroke risk profile and not the perceived success or failure of ablation…" [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H247698617"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">"Society guideline links: Atrial fibrillation"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116934.html" rel="external">"Society guideline links: Catheter ablation of atrial fibrillation"</a>.)</p><p class="headingAnchor" id="H1041764018"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence, timing, and mechanism </strong>– The risk of stroke, transient ischemic attack, or other significant manifestation of embolization is increased, compared to baseline risk, at the time of catheter ablation (CA) for atrial fibrillation. (See <a class="local">'Incidence, timing, and mechanism of embolism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of transesophageal echocardiography </strong>– We perform a preprocedural transesophageal echocardiogram or cardiac magnetic resonance imaging (MRI) in most patients undergoing CA. The finding of intracardiac thrombus is a contraindication to the procedure. (See <a class="local">'Role of transesophageal echocardiography'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preprocedural issues </strong>–<strong> </strong>Most patients scheduled to undergo CA who have been receiving long-term oral anticoagulation should continue to do so until the procedure. For those low-risk patients who have not been receiving long-term anticoagulation, including those in sinus rhythm at the time of the procedure, we suggest at least three weeks of effective anticoagulation prior to CA rather than no preprocedural anticoagulation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). An alternate approach is presented above. (See <a class="local">'Preprocedural issues'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Periprocedural issues </strong>–<strong> </strong>All patients should receive intraprocedural anticoagulation with intravenous heparin, irrespective of the patient’s baseline thromboembolic risk and whether or not the procedure is performed on uninterrupted <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>. (See <a class="local">'Periprocedural issues'</a> above.)</p><p></p><p class="bulletIndent1">For patients taking long-term oral anticoagulant with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> who present for CA, we recommend continuing such therapy rather than stopping and using a heparin bridge (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>).</p><p></p><p class="bulletIndent1">For patients taking long-term oral anticoagulant with a newer oral anticoagulant who present for CA, we suggest discontinuing such therapy before the procedure rather than continuing it (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Periprocedural issues'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients taking DOACs </strong>–<strong> </strong>For the uncommon patient who is at very high risk of a periprocedural stroke, it is reasonable to not discontinue direct oral anticoagulants (DOAC; also referred to as non-vitamin K oral anticoagulants [NOAC]). (See <a class="local">'Patients taking DOACs'</a> above.)</p><p></p><p class="bulletIndent1">DOAC may be restarted four to six hours after sheath pull. Alternatively, DOAC may be restarted the morning after the procedure in patients who are treated overnight with either intravenous <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (no bolus; drip at 1000 to 1200 units per hour starting six hours after sheath pull and continued until the morning after the procedure) or low molecular weight heparin (<a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> 0.5 mg/kg; typically a single dose at six hours after sheath pull). (See <a class="local">'Patients taking DOACs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term anticoagulation </strong>–<strong> </strong>Oral anticoagulation is continued for at least two months after the procedure in all patients. After two months, the decision to continue anticoagulation should be based on the patient’s risk factors for stroke and risk of bleeding and not on the type of AF or outcome of the procedure. (See <a class="local">'Long-term anticoagulation'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jamil S, Batool S, Ehsan Ullah S, et al. Comparison of Interrupted and Uninterrupted Anticoagulation Therapy for Patients With Atrial Fibrillation Undergoing Catheter Ablation: A Meta-Analysis. Cureus 2022; 14:e30742.</a></li><li><a class="nounderline abstract_t">Miyamoto K, Murata S, Takegami M, et al. Real-world comparison of in-hospital complications after catheter ablation for atrial fibrillation between non-antivitamin K anticoagulants and warfarin: A propensity-matched analysis using nation-wide database. Int J Cardiol Heart Vasc 2023; 44:101174.</a></li><li><a class="nounderline abstract_t">Spragg DD, Dalal D, Cheema A, et al. Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol 2008; 19:627.</a></li><li><a class="nounderline abstract_t">Cappato R, Calkins H, Chen SA, et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 2009; 53:1798.</a></li><li><a class="nounderline abstract_t">Page SP, Herring N, Hunter RJ, et al. Periprocedural stroke risk in patients undergoing catheter ablation for atrial fibrillation on uninterrupted warfarin. J Cardiovasc Electrophysiol 2014; 25:585.</a></li><li><a class="nounderline abstract_t">Kosiuk J, Kornej J, Bollmann A, et al. Early cerebral thromboembolic complications after radiofrequency catheter ablation of atrial fibrillation: incidence, characteristics, and risk factors. Heart Rhythm 2014; 11:1934.</a></li><li><a class="nounderline abstract_t">Michaud GF. Silent cerebral embolism during catheter ablation of atrial fibrillation: how concerned should we be? Circulation 2010; 122:1662.</a></li><li><a class="nounderline abstract_t">Gaita F, Caponi D, Pianelli M, et al. Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation 2010; 122:1667.</a></li><li><a class="nounderline abstract_t">Schrickel JW, Lickfett L, Lewalter T, et al. Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation. Europace 2010; 12:52.</a></li><li><a class="nounderline abstract_t">Herm J, Fiebach JB, Koch L, et al. Neuropsychological effects of MRI-detected brain lesions after left atrial catheter ablation for atrial fibrillation: long-term results of the MACPAF study. Circ Arrhythm Electrophysiol 2013; 6:843.</a></li><li><a class="nounderline abstract_t">Verma A, Debruyne P, Nardi S, et al. Evaluation and reduction of asymptomatic cerebral embolism in ablation of atrial fibrillation, but high prevalence of chronic silent infarction: results of the evaluation of reduction of asymptomatic cerebral embolism trial. Circ Arrhythm Electrophysiol 2013; 6:835.</a></li><li><a class="nounderline abstract_t">Ichiki H, Oketani N, Ishida S, et al. The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran. Pacing Clin Electrophysiol 2013; 36:1328.</a></li><li><a class="nounderline abstract_t">Haines DE. ERACEing the risk of cerebral embolism from atrial fibrillation ablation. Circ Arrhythm Electrophysiol 2013; 6:827.</a></li><li><a class="nounderline abstract_t">Medi C, Evered L, Silbert B, et al. Subtle post-procedural cognitive dysfunction after atrial fibrillation ablation. J Am Coll Cardiol 2013; 62:531.</a></li><li><a class="nounderline abstract_t">January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019; 140:e125.</a></li><li><a class="nounderline abstract_t">Shah RR, Pillai A, Schafer P, et al. Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation. Am J Cardiol 2017; 120:404.</a></li><li><a class="nounderline abstract_t">Kim JS, She F, Jongnarangsin K, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2013; 10:483.</a></li><li><a class="nounderline abstract_t">Nin T, Sairaku A, Yoshida Y, et al. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol 2013; 36:172.</a></li><li><a class="nounderline abstract_t">Winkle RA, Mead RH, Engel G, et al. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2012; 23:264.</a></li><li><a class="nounderline abstract_t">Bassiouny M, Saliba W, Rickard J, et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 2013; 6:460.</a></li><li><a class="nounderline abstract_t">Maddox W, Kay GN, Yamada T, et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. J Cardiovasc Electrophysiol 2013; 24:861.</a></li><li><a class="nounderline abstract_t">Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2014; 63:982.</a></li><li><a class="nounderline abstract_t">Dillier R, Ammar S, Hessling G, et al. Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures. Circ Arrhythm Electrophysiol 2014; 7:576.</a></li><li><a class="nounderline abstract_t">Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2012; 59:1168.</a></li><li><a class="nounderline abstract_t">Providência R, Albenque JP, Combes S, et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 2014; 100:324.</a></li><li><a class="nounderline abstract_t">Bin Abdulhak AA, Khan AR, Tleyjeh IM, et al. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace 2013; 15:1412.</a></li><li><a class="nounderline abstract_t">Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace 2013; 15:1407.</a></li><li><a class="nounderline abstract_t">Wu S, Yang YM, Zhu J, et al. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation. Am J Cardiol 2016; 117:926.</a></li><li><a class="nounderline abstract_t">Knight BP. Transesophageal echocardiography before atrial fibrillation ablation: looking before cooking. J Am Coll Cardiol 2009; 54:2040.</a></li><li><a class="nounderline abstract_t">Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thor</a></li><li><a class="nounderline abstract_t">Rathi VK, Reddy ST, Anreddy S, et al. Contrast-enhanced CMR is equally effective as TEE in the evaluation of left atrial appendage thrombus in patients with atrial fibrillation undergoing pulmonary vein isolation procedure. Heart Rhythm 2013; 10:1021.</a></li><li><a class="nounderline abstract_t">Chen J, Zhang H, Zhu D, et al. Cardiac MRI for detecting left atrial/left atrial appendage thrombus in patients with atrial fibrillation : Meta-analysis and systematic review. Herz 2019; 44:390.</a></li><li><a class="nounderline abstract_t">Puwanant S, Varr BC, Shrestha K, et al. Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation. J Am Coll Cardiol 2009; 54:2032.</a></li><li><a class="nounderline abstract_t">Saksena S, Sra J, Jordaens L, et al. A prospective comparison of cardiac imaging using intracardiac echocardiography with transesophageal echocardiography in patients with atrial fibrillation: the intracardiac echocardiography guided cardioversion helps interventional procedures study. Circ Arrhythm Electrophysiol 2010; 3:571.</a></li><li><a class="nounderline abstract_t">Martinez MW, Kirsch J, Williamson EE, et al. Utility of nongated multidetector computed tomography for detection of left atrial thrombus in patients undergoing catheter ablation of atrial fibrillation. JACC Cardiovasc Imaging 2009; 2:69.</a></li><li><a class="nounderline abstract_t">Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014; 129:2638.</a></li><li><a class="nounderline abstract_t">Santangeli P, Di Biase L, Horton R, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012; 5:302.</a></li><li><a class="nounderline abstract_t">Kuwahara T, Takahashi A, Takahashi Y, et al. Prevention of periprocedural ischemic stroke and management of hemorrhagic complications in atrial fibrillation ablation under continuous warfarin administration. J Cardiovasc Electrophysiol 2013; 24:510.</a></li><li><a class="nounderline abstract_t">Di Biase L, Gaita F, Toso E, et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. Heart Rhythm 2014; 11:791.</a></li><li><a class="nounderline abstract_t">Kim JS, Jongnarangsin K, Latchamsetty R, et al. The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin. Circ Arrhythm Electrophysiol 2013; 6:302.</a></li><li><a class="nounderline abstract_t">Yu HT, Shim J, Park J, et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. Eur Heart J 2019; 40:1531.</a></li><li><a class="nounderline abstract_t">Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med 2017; 376:1627.</a></li><li><a class="nounderline abstract_t">Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015; 36:1805.</a></li><li><a class="nounderline abstract_t">Hohnloser SH, Camm J, Cappato R, et al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J 2019; 40:3013.</a></li><li><a class="nounderline abstract_t">Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J 2018; 39:2942.</a></li><li><a class="nounderline abstract_t">Sticherling C, Marin F, Birnie D, et al. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace 2015; 17:1197.</a></li><li><a class="nounderline abstract_t">Eitel C, Koch J, Sommer P, et al. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace 2013; 15:1587.</a></li><li><a class="nounderline abstract_t">Karasoy D, Gislason GH, Hansen J, et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark. Eur Heart J 2015; 36:307.</a></li><li><a class="nounderline abstract_t">Schreiber D, Rostock T, Fröhlich M, et al. Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success. Circ Arrhythm Electrophysiol 2015; 8:308.</a></li><li><a class="nounderline abstract_t">Jacobs V, May HT, Bair TL, et al. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation. Heart Rhythm 2015; 12:681.</a></li><li><a class="nounderline abstract_t">Kaufman ES, Waldo AL. The impact of asymptomatic atrial fibrillation. J Am Coll Cardiol 2004; 43:53.</a></li><li><a class="nounderline abstract_t">Saad EB, Marrouche NF, Saad CP, et al. Pulmonary vein stenosis after catheter ablation of atrial fibrillation: emergence of a new clinical syndrome. Ann Intern Med 2003; 138:634.</a></li><li><a class="nounderline abstract_t">Pappone C, Oreto G, Rosanio S, et al. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation 2001; 104:2539.</a></li><li><a class="nounderline abstract_t">Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003; 42:185.</a></li><li><a class="nounderline abstract_t">Verma A, Wazni OM, Marrouche NF, et al. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol 2005; 45:285.</a></li><li><a class="nounderline abstract_t">Romero J, Cerrud-Rodriguez RC, Diaz JC, et al. Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: A systematic review and meta-analysis. J Cardiovasc Electrophysiol 2019; 30:1250.</a></li><li><a class="nounderline abstract_t">Lin YJ, Chao TF, Tsao HM, et al. Successful catheter ablation reduces the risk of cardiovascular events in atrial fibrillation patients with CHA2DS2-VASc risk score of 1 and higher. Europace 2013; 15:676.</a></li><li><a class="nounderline abstract_t">Bunch TJ, Crandall BG, Weiss JP, et al. Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol 2011; 22:839.</a></li><li><a class="nounderline abstract_t">Hunter RJ, McCready J, Diab I, et al. Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. Heart 2012; 98:48.</a></li><li><a class="nounderline abstract_t">Oral H, Chugh A, Ozaydin M, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006; 114:759.</a></li><li><a class="nounderline abstract_t">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64:e1.</a></li><li><a class="nounderline abstract_t">January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74:104.</a></li></ol></div><div id="topicVersionRevision">Topic 94502 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36447720" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Comparison of Interrupted and Uninterrupted Anticoagulation Therapy for Patients With Atrial Fibrillation Undergoing Catheter Ablation: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36687335" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Real-world comparison of in-hospital complications after catheter ablation for atrial fibrillation between non-antivitamin K anticoagulants and warfarin: A propensity-matched analysis using nation-wide database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18462327" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Complications of catheter ablation for atrial fibrillation: incidence and predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19422987" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24641450" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Periprocedural stroke risk in patients undergoing catheter ablation for atrial fibrillation on uninterrupted warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25086257" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Early cerebral thromboembolic complications after radiofrequency catheter ablation of atrial fibrillation: incidence, characteristics, and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20937971" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Silent cerebral embolism during catheter ablation of atrial fibrillation: how concerned should we be?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20937975" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19933517" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23989301" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Neuropsychological effects of MRI-detected brain lesions after left atrial catheter ablation for atrial fibrillation: long-term results of the MACPAF study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23983245" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Evaluation and reduction of asymptomatic cerebral embolism in ablation of atrial fibrillation, but high prevalence of chronic silent infarction: results of the evaluation of reduction of asymptomatic cerebral embolism trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23952291" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24129202" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : ERACEing the risk of cerebral embolism from atrial fibrillation ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23684686" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Subtle post-procedural cognitive dysfunction after atrial fibrillation ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30686041" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28595862" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23237911" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23121681" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21955008" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The use of dabigatran immediately after atrial fibrillation ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23553523" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23577951" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24412445" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24970293" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22305113" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23878175" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23954918" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23954917" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26803384" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19926010" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Transesophageal echocardiography before atrial fibrillation ablation: looking before cooking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22386883" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23454807" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Contrast-enhanced CMR is equally effective as TEE in the evaluation of left atrial appendage thrombus in patients with atrial fibrillation undergoing pulmonary vein isolation procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29374292" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cardiac MRI for detecting left atrial/left atrial appendage thrombus in patients with atrial fibrillation : Meta-analysis and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19926009" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20852299" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A prospective comparison of cardiac imaging using intracardiac echocardiography with transesophageal echocardiography in patients with atrial fibrillation: the intracardiac echocardiography guided cardioversion helps interventional procedures study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19356536" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Utility of nongated multidetector computed tomography for detection of left atrial thrombus in patients undergoing catheter ablation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24744272" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271713" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23350877" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prevention of periprocedural ischemic stroke and management of hemorrhagic complications in atrial fibrillation ablation under continuous warfarin administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24607716" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23443620" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30590600" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28317415" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25975659" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30976787" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29579168" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26105732" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23703362" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25368205" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25744570" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25546809" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14715183" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The impact of asymptomatic atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12693885" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pulmonary vein stenosis after catheter ablation of atrial fibrillation: emergence of a new clinical syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11714647" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12875749" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15653029" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31257677" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23193161" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Successful catheter ablation reduces the risk of cardiovascular events in atrial fibrillation patients with CHA2DS2-VASc risk score of 1 and higher.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21410581" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21930724" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908760" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24685669" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30703431" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
